The fibrin-derived peptide Bβ15–42 (FX06) has been proven to attenuate ischemia/reperfusion injury. We tested the hypothesis that Bβ15–42 improves survival rate and neurocognitive recovery after cardiopulmonary resuscitation.
Pig and mouse model of cardiopulmonary resuscitation.
Two university hospitals.
Pigs and mice.
Pigs (n = 16) were subjected to 8-minute cardiac arrest. Successful resuscitated pigs (n = 12) were randomized either to 3 mg/kg Bβ15–42 followed by a continuous infusion of 1 mg/kg/hr for 5 hours (pFX06; n = 6) or the control group (pCONTROL; n = 6). Cardiac damage, function, and hemodynamics were recorded up to 8 hours. Mice (n = 52) were subjected to 4-minute cardiac arrest followed by cardiopulmonary resuscitation, and randomized either to two boli of 2.4 mg/kg Bβ15–42 (mFX06; n = 26) or the control group (mCONTROL; n = 26). Fourteen-day survival rate, neurocognitive function, and endothelial integrity (additional experiment with n = 26 mice) were evaluated.
Measurements and Main Results:
Bβ15–42 reduced cumulative fluid intake (3,500 [2,600–4,200] vs 6,800 [5,700–7,400] mL; p = 0.004) within 8 hours in pigs. In mice, Bβ15–42 improved 14-day survival rate (mFX06 vs mCONTROL; 11/26 vs 6/26; p < 0.05) and fastened neurocognitive recovery in the Water-Maze test (15/26 vs 9/26 mice with competence to perform test; p < 0.05). Bβ15–42-treated mice showed a significant higher length of intact pulmonary endothelium and reduced pulmonary leukocyte infiltration.
This study confirms the new concept of an important role of fibrin derivatives in global ischemia/reperfusion injury, which can be attenuated by the fibrin-derived peptide Bβ15–42.